OM Stock Price, Outset Medical Inc Quote, Chart

Market Summary

USD3.62+0.10

Market Closed

2.84%

OM Stock Price

View Fullscreen

OM RSI Chart

OM Valuation

Market Cap

187.2M

Price/Earnings (Trailing)

-1.11

Price/Sales (Trailing)

1.5

EV/EBITDA

-2.4

Price/Free Cashflow

-1.38

OM Price/Sales (Trailing)

OM Profitability

EBT Margin

-134.54%

Return on Equity

-181.04%

Return on Assets

-48.73%

Free Cashflow Yield

-72.38%

OM Fundamentals

OM Revenue

Revenue (TTM)

125.1M

Rev. Growth (Yr)

-15.83%

Rev. Growth (Qtr)

-7.67%

OM Earnings

Earnings (TTM)

-168.7M

Earnings Growth (Yr)

9.26%

Earnings Growth (Qtr)

-3.37%

Breaking Down OM Revenue

Last 7 days

17.9%

Last 30 days

67.6%

Last 90 days

6.2%

Trailing 12 Months

-82.8%

How does OM drawdown profile look like?

OM Financial Health

Current Ratio

6.42

Debt/Equity

2.11

Debt/Cashflow

-0.67

OM Investor Care

Shares Dilution (1Y)

5.07%

Diluted EPS (TTM)

-3.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	125.1M	0	0	0
2023	118.3M	129.3M	131.9M	130.4M
2022	110.2M	110.1M	111.5M	115.4M
2021	65.7M	79.1M	91.7M	102.6M
2020	19.8M	28.6M	39.8M	49.9M
2019	5.3M	8.5M	11.8M	15.1M
2018	0	0	0	2.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Outset Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 10, 2024	racine jean-olivier	sold	-27,160	3.27	-8,306	chief technology officer
Mar 15, 2024	nash marc	sold	-5,092	2.13	-2,391	svp operations and r&d
Mar 12, 2024	lang brent d.	acquired	-	-	108,024	-
Mar 01, 2024	ahmed nabeel	sold	-4,989	3.15	-1,584	chief financial officer
Feb 29, 2024	ahmed nabeel	acquired	4,245	2.68	1,584	chief financial officer
Feb 23, 2024	trigg leslie	acquired	-	-	131,687	chair and ceo
Feb 23, 2024	ahmed nabeel	acquired	-	-	20,922	chief financial officer
Feb 23, 2024	trigg leslie	sold (taxes)	-169,401	3.72	-45,538	chair and ceo
Feb 23, 2024	ahmed nabeel	sold (taxes)	-39,577	3.72	-10,639	chief financial officer
Feb 15, 2024	brottem john l.	sold	-11,927	3.57	-3,341	general counsel

Which funds bought or sold OM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-1.09	-733,895	501,375	-%
May 16, 2024	COMERICA BANK	sold off	-100	-4,371	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.93	-33,366	11,158	-%
May 16, 2024	Mubadala Investment Co PJSC	unchanged	-	-4,595,520	3,198,130	0.01%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	37.15	-562,478	724,058	-%
May 15, 2024	Royal Bank of Canada	reduced	-85.59	-178,000	10,000	-%
May 15, 2024	T. Rowe Price Investment Management, Inc.	sold off	-100	-17,133,000	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-17.58	-885,822	452,694	-%
May 15, 2024	JACOBS LEVY EQUITY MANAGEMENT, INC	added	29.75	-775,945	883,573	-%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	added	2.21	-235,399	170,070	0.03%

Are Funds Buying or Selling OM?

Are funds buying OM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OM

No. of Funds

Unveiling Outset Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	ameriprise financial inc	10.12%	5,112,408	SC 13G/A
Feb 14, 2024	t. rowe price investment management, inc.	6.3%	3,166,747	SC 13G
Feb 14, 2024	ameriprise financial inc	5.94%	2,982,490	SC 13G
Feb 13, 2024	bellevue group ag	1.1%	1,760,134	SC 13G/A
Feb 13, 2024	vanguard group inc	7.85%	3,941,367	SC 13G/A
Feb 09, 2024	morgan stanley	6.8%	3,413,343	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.6%	3,795,419	SC 13G/A
Jan 23, 2024	jpmorgan chase & co	9.4%	4,745,757	SC 13G/A
Sep 08, 2023	jpmorgan chase & co	10.0%	5,008,104	SC 13G/A

Recent SEC filings of Outset Medical Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 10, 2024	144	Notice of Insider Sale Intent
May 10, 2024	4	Insider Trading

Peers (Alternatives to Outset Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Outset Medical Inc News

Latest updates

Outset Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-7.7%	28,168,000	30,507,000	30,362,000	36,040,000	33,467,000	32,007,000	27,761,000	25,057,000	30,550,000	28,152,000	26,318,000	25,216,000	22,916,000	17,247,000	13,756,000	11,742,000	7,190,000	7,085,000	2,630,000	2,872,000	2,491,000
Gross Profit	6.5%	8,215,000	7,712,000	7,157,000	7,703,000	6,428,000	5,273,000	4,336,000	3,782,000	4,442,000	3,321,000	2,946,000	1,052,000	289,000	417,000	-5,126,000	-4,764,000	-3,564,000	-2,780,000	-5,294,000	-4,470,000	-5,258,000
Operating Expenses	0.1%	45,127,000	45,065,000	52,611,000	51,181,000	49,913,000	45,097,000	45,335,000	47,503,000	40,917,000	44,120,000	33,084,000	30,958,000	29,965,000	32,032,000	35,607,000	20,145,000	16,646,000	-	13,156,000	-	-
S&GA Expenses	-5.2%	21,048,000	22,194,000	24,720,000	24,985,000	24,333,000	23,631,000	22,276,000	23,198,000	20,377,000	22,991,000	15,726,000	13,204,000	13,149,000	15,198,000	13,344,000	9,244,000	7,282,000	-	5,009,000	-	-
R&D Expenses	0.8%	12,635,000	12,532,000	16,076,000	14,906,000	13,793,000	11,444,000	13,059,000	13,521,000	10,831,000	11,410,000	9,729,000	8,032,000	7,570,000	7,784,000	9,175,000	6,053,000	5,838,000	-	5,708,000	-	-
EBITDA Margin	0.6%	-1.17	-1.18	-1.20	-1.20	-1.34	-1.33	-1.39	-1.32	-1.19	-1.22	-1.26	-1.61	-	-	-	-	-	-	-	-	-
Interest Expenses	74.7%	5,968,000	3,417,000	3,213,000	3,103,000	2,942,000	2,096,000	567,000	481,000	422,000	431,000	431,000	431,000	422,000	430,000	428,000	1,032,000	1,001,000	-	1,047,000	-	-
Income Taxes	44.6%	162,000	112,000	86,000	133,000	192,000	64,000	20,000	96,000	115,000	125,000	-	35,000	39,000	-	-	-	-	-	20,000	-	-
Earnings Before Taxes	-3.4%	-39,782,000	-38,488,000	-46,094,000	-43,913,000	-43,779,000	-41,380,000	-40,761,000	-43,743,000	-36,777,000	-41,107,000	-30,470,000	-30,173,000	-29,986,000	-32,043,000	-42,294,000	-26,505,000	-20,650,000	-	-15,382,000	-	-
EBT Margin	-1.8%	-1.35	-1.32	-1.33	-1.31	-1.43	-1.41	-1.46	-1.38	-1.26	-1.28	-1.34	-1.70	-	-	-	-	-	-	-	-	-
Net Income	-3.4%	-39,900,000	-38,600,000	-46,180,000	-44,046,000	-43,971,000	-41,444,000	-40,781,000	-43,839,000	-36,892,000	-41,232,000	-30,470,000	-30,208,000	-30,025,000	-32,043,000	-42,294,000	-26,505,000	-20,650,000	-19,446,000	-15,402,000	-17,029,000	-16,422,000
Net Income Margin	-1.8%	-1.35	-1.33	-1.33	-1.32	-1.44	-1.41	-1.46	-1.38	-1.26	-1.29	-1.34	-1.70	-	-	-	-	-	-	-	-	-
Free Cashflow	-81.5%	-46,266,000	-25,495,000	-34,781,000	-28,971,000	-45,566,000	-36,616,000	-37,053,000	-40,572,000	-39,813,000	-33,527,000	-28,622,000	-31,688,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	10.3%	346	314	308	334	363	400	366	401	432	463	489	505	380	404	426	313	201	88.00	151
Current Assets	11.7%	325	291	284	309	337	374	310	346	377	410	433	448	322	346	368	-	-	80.00	148
Cash Equivalents	-53.0%	32.00	69.00	36.00	36.00	36.00	73.00	64.00	75.00	114	182	231	274	252	295	311	142	158	37.00	33.00
Inventory	13.5%	56.00	49.00	48.00	44.00	48.00	51.00	55.00	54.00	43.00	39.00	34.00	29.00	25.00	18.00	12.00	-	-	5.00	3.00
Net PPE	-9.9%	12.00	13.00	14.00	15.00	15.00	16.00	16.00	15.00	14.00	13.00	15.00	15.00	16.00	15.00	14.00	-	-	8.00	2.00
Liabilities	32.5%	253	191	155	151	146	154	87.00	91.00	86.00	89.00	79.00	74.00	73.00	75.00	72.00	65.00	58.00	51.00	47.00
Current Liabilities	-8.4%	51.00	55.00	53.00	49.00	44.00	52.00	50.00	55.00	49.00	52.00	41.00	35.00	35.00	37.00	33.00	-	-	25.00	10.00
Long Term Debt	51.3%	197	130	97.00	97.00	96.00	96.00	30.00	29.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	-	-	22.00	28.00
LT Debt, Current	-	-	-	-	-	-	-	-	1.00	-	-	-	-	-	-	-	-	-	8.00	-
LT Debt, Non Current	-100.0%	-	130	97.00	97.00	96.00	96.00	30.00	29.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	-	-	22.00	28.00
Shareholder's Equity	-24.2%	93.00	123	152	183	216	246	279	310	345	374	410	431	307	329	354	-	-	-	-
Retained Earnings	-4.0%	-1,000	-961	-923	-876	-832	-788	-747	-706	-662	-625	-584	-554	-524	-494	-462	-	-	-372	-287
Additional Paid-In Capital	1.0%	1,095	1,085	1,075	1,060	1,049	1,035	1,027	1,017	1,009	1,000	994	985	831	823	816	-	-	0.00	-
Shares Outstanding	2.8%	52.00	50.00	50.00	50.00	49.00	48.00	48.00	48.00	48.00	47.00	47.00	46.00	-	-	-	-	-	-	-
Float	-	-	-	-	1,100	-	-	-	709	-	-	-	1,700	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	-87.8%	-45,912	-24,442	-33,999	-28,176	-44,756	-34,507	-34,312	-38,575	-38,335	-32,676	-28,131	-30,841	-38,616	-25,840	-29,116	-19,166	-24,893	-	-	-
Share Based Compensation	-9.8%	8,203	9,098	10,893	10,105	8,538	7,353	7,430	7,414	5,006	4,792	2,864	3,937	5,852	6,268	13,908	683	580	-	-	-
Cashflow From Investing	-352.0%	-59,031	23,425	29,805	27,153	2,643	-51,748	20,159	-1,316	-33,390	-16,418	-21,822	-97,460	-6,807	10,358	-31,882	6,312	19,159	-	-	-
Cashflow From Financing	106.5%	68,610	33,229	4,103	1,043	5,277	65,600	2,533	1,042	3,723	934	6,187	150,808	2,218	-873	259,758	27.00	126,770	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OM Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Revenue	$ 28,168	$ 33,467
Cost of revenue:
Cost of revenue	19,953	27,039
Gross profit	8,215	6,428
Operating expenses:
Research and development	12,635	13,793
Sales and marketing	21,048	24,333
General and administrative	11,444	11,787
Total operating expenses	45,127	49,913
Loss from operations	(36,912)	(43,485)
Interest income and other income, net	3,098	2,648
Interest expense	(5,968)	(2,942)
Loss before provision for income taxes	(39,782)	(43,779)
Provision for income taxes	162	192
Net loss	$ (39,944)	$ (43,971)
Net loss per share, basic	$ (0.78)	$ (0.9)
Net loss per share,diluted	$ (0.78)	$ (0.9)
Shares used in computing net loss per share, basic	50,901	48,783
Shares used in computing net loss per share, diluted	50,901	48,783
Product Revenue
Revenue:
Revenue	$ 20,428	$ 27,779
Cost of revenue:
Cost of revenue	12,581	20,817
Service and Other Revenue
Revenue:
Revenue	7,740	5,688
Cost of revenue:
Cost of revenue	$ 7,372	$ 6,222

OM Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 32,176	$ 68,509
Short-term investments	194,743	134,815
Accounts receivable, net	36,478	32,980
Inventories	55,839	49,215
Prepaid expenses and other current assets	6,155	5,700
Total current assets	325,391	291,219
Restricted cash	3,329	3,329
Property and equipment, net	11,953	13,273
Operating lease right-of-use assets	5,029	5,375
Other assets	540	605
Total assets	346,242	313,801
Current liabilities:
Accounts payable	6,773	5,827
Accrued compensation and related benefits	14,248	19,005
Accrued expenses and other current liabilities	11,968	13,459
Accrued warranty liability	3,200	3,712
Deferred revenue, current	12,839	11,727
Operating lease liabilities, current	1,642	1,593
Total current liabilities	50,670	55,323
Accrued interest	1,319	896
Deferred revenue	186	101
Operating lease liabilities	4,054	4,482
Term loan	196,813	130,113
Total liabilities	253,042	190,915
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 300,000 shares authorized as of March 31, 2024 and December 31, 2023; 51,702 and 50,317 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	52	50
Additional paid-in capital	1,095,097	1,084,515
Accumulated other comprehensive loss	(258)	68
Accumulated deficit	(1,001,691)	(961,747)
Total stockholders' equity	93,200	122,886
Total liabilities and stockholders' equity	$ 346,242	$ 313,801

About Outset Medical Inc

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

CEO	Ms. Leslie L. Trigg
WEBSITE	outsetmedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	518

Outset Medical Inc Frequently Asked Questions

What is the ticker symbol for Outset Medical Inc? What does OM stand for in stocks?

OM is the stock ticker symbol of Outset Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Outset Medical Inc (OM)?

As of Fri May 17 2024, market cap of Outset Medical Inc is 187.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OM stock?

You can check OM's fair value in chart for subscribers.

What is the fair value of OM stock?

You can check OM's fair value in chart for subscribers. The fair value of Outset Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Outset Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Outset Medical Inc a good stock to buy?

The fair value guage provides a quick view whether OM is over valued or under valued. Whether Outset Medical Inc is cheap or expensive depends on the assumptions which impact Outset Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OM.

What is Outset Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OM's PE ratio (Price to Earnings) is -1.11 and Price to Sales (PS) ratio is 1.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OM PE ratio will change depending on the future growth rate expectations of investors.